The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Multiple Myeloma is a type of blood cancer that develops in plasma cells — white blood cells responsible for producing ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Retired Major General David Weishaar, didn’t intend on making the national guard his career. “But 42 years later, I decided it was time to retire and I did ...

(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...